Abstract:Abstract CUP is a relatively common diagnosis that accounts for 3-9% of all cancers. The prognosis is poor with median survival of approximately 9 months. The identification of the primary tumor and therapy targets could improve the survival of these patients. We employed the BostonGene Tumor PortraitTM platform to interrogate 19 CUP cases. Trained on >19,000 samples and validated on 28,000 samples from independent datasets, the machine-learning based algorithm integrates whole-exome and RNA sequencing (WES and RNAseq) analysis to characterize cancer drivers, the tumor microenvironment, potential targets, tumor composition, molecular signatures, and site of origin (94% sensitivity and 99% specificity). The predicted tissue of origin was considered acceptable when it was compatible with tumor histopathology and immunoprofile, and included in the differential diagnosis of radiologic studies. The discovered biomarkers and possible treatments were discussed during our multidisciplinary precision oncology meeting. 16 out of 19 CUP cases (84%) had an acceptable predicted tissue of origin. Two cases lacked clinical evidence to support the predicted primary tumor, and 1 case failed RNAseq. Lung accounted for most of the sites of origin (31%) followed by gastrointestinal (15%) and breast cancers (8%). Other diagnoses included melanoma, uterine, bladder, and renal carcinomas, among others. Except for one case, a clinically significant biomarker or target was found. Those included relevant mutational signatures (e.g., homologous recombination deficiency, DNA mismatch repair), genetic characteristics (high tumor mutational burden (TMB), microsatellite instability), activating alterations (FGFR1, MYC, ERBB2 amplifications; NCOA4::RET fusion), loss of function in tumor suppressor genes (TP53, FANCA, ATM), and gene overexpression (ER). Further, microenvironment analysis characterized the tumor immune infiltrate and the level of RNA expression of PD-L1, PD-L2, and CTLA4. These oncology biomarkers and potential targets are of significant value independent of tissue of origin. In addition, mutations in NF1, KRAS, TP53, MSH2, BRCA1, and PTEN were found and validated by commercially available targeted NGS panels. Based on CUP tumor profiling by this platform, positive treatment response has been observed in 3 out of 4 CUP patients thus far, e.g., one patient with metastatic disease that showed high TMB and immune infiltrated microenvironment treated with Ipilimumab and Nivolumab had a sustained response. Therapy in oncology is often determined by the tissue origin, making CUP a therapeutic challenge. In this study, we demonstrate the application of an integrative WES and RNAseq platform to not only predict the site of origin, but also to identify relevant biomarkers and therapeutic targets in CUP. Citation Format: Majd Al Assaad, Michael Sigouros, Jyothi Manohar, Daniela Guevara, Zoia Antysheva, Daria Kiriy, Alexandra Boyko, Naira Samarina, Nara Shin, Viktor Svekolkin, Svetlana Podsvirova, Noel English, Alaina Villarreal, Brianna McKenna, Cagdas Tazearslan, Diana Shamsutdinova, Vladimir Kushnarev, Troy Kane, David Wilkes, Manish Shah, Barbara Ma, Scott T. Tagawa, David Nanus, Jones Nauseef, Olivier Elemento, Juan Miguel Mosquera, Cora N. Sternberg. Cancer of unknown Primary (CUP): Beyond the identification of the site of origin by an integrative genomic approach [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2143.

Machine learning for genetics-based classification and treatment response prediction in cancer of unknown primary

Targeted Next-Generation Sequencing (ngs) of Carcinoma of Unknown Primary Site (cup): Actionable Genomic Alterations (ga) and New Routes to Targeted Therapies.

The Diagnosis and Treatment for a Patient with Cancer of Unknown Primary: A Case Report.

Diagnostic efficacy of deep learning-based prediction of origin for patients with cancers of unknown primary.

Abstract 2143: Cancer of unknown Primary (CUP): Beyond the identification of the site of origin by an integrative genomic approach

Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology

Abstract 5045: Genomics and pathology based deep learning to predict cancers of unknown primary

Cancer of Unknown Primary origin in the genomic era: Elucidating the dark box of cancer

A cfDNA methylation-based tissue-of-origin classifier for cancers of unknown primary

Altered Signaling Pathways Revealed by Comprehensive Genomic Profiling in Patients With Unknown Primary Tumors

Case Report: Molecular Profiling Assists in the Diagnosis and Treatment of Cancer of Unknown Primary

Deep Learning-based Computational Pathology Predicts Origins for Cancers of Unknown Primary

Deciphering the origin and therapeutic targets of cancer of unknown primary: a case report that illustrates the power of integrative whole-exome and transcriptome sequencing analysis

Comprehensive genomic and clinical analysis of cancer of unknown primary site in Chinese patients.

Advances in Machine Learning for Tumour Classification in Cancer of Unknown Primary: A Mini-Review

The practical utility of AI-assisted molecular profiling in the diagnosis and management of cancer of unknown primary: an updated review

Utility of liquid biopsy for predicting cancer type and informing treatment of carcinoma with unknown primary.

Current Status and Progress of Diagnostic Techniques for Cancer of Unknown Primary

ctDNA analysis in patients with cancer of unknown primary and its value in guiding targeted treatment when combined with predicted cancer types by 90-gene reverse-transcription polymerase chain reaction assay.

Abstract 2167: Machine learning-based tissue of origin classification for cancer of unknown primary diagnostics using genome-wide mutation features

Diagnosis Progress of Carcinoma of Unknown Primary